FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 589 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Specific Lung Cancer Screening and Treatment Policies Urgently Needed to Address... March 23, 2022 From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver... July 3, 2026 Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... November 20, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Poherdy Reducing Health Care Disparities Through Cancer Clinical Trials Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma... Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each...
